Skip navigation
Watchlist Sponsored By :

ALSO IN EARNINGS


Current DateTime: 06:20:25 11 Feb 2012
LinksList Documentid: 35909644

Current DateTime: 06:20:27 11 Feb 2012
LinksList Documentid: 24355697
  • The World's Best Beers

      Craft brewers account for only about five percent of the US market, but that may be changing.

  • Fashion Stocks Traders Love

      Over the past couple of months, the “Fast Money” traders weighed in on companies that stood out.

  • Best in Show

      Who is the top dog at the Westminster Kennel Club Dog Show


Current DateTime: 06:20:27 11 Feb 2012
LinksList Documentid: 23452764
Expiration DateTime: 2/11/2012 6:21:24 AM

MOST SHARED


Current DateTime: 06:20:28 11 Feb 2012
LinksList Documentid: 31330905
Expiration DateTime: 2/11/2012 6:21:45 AM

MOST POPULAR


Current DateTime: 06:20:28 11 Feb 2012
LinksList Documentid: 35819650
    • Road Warriors

        All the gadgets and gear a savvy frequent traveler needs to navigate the global economy.

HOT ON FACEBOOK

Schering-Plough's Loss Is Narrower than Expected

Published: Tuesday, 12 Feb 2008 | 7:55 AM ET
Text Size
By: Reuters

Schering-Plough Tuesday reported a quarterly loss as special charges from its acquisition of Organon Biosciences late last year offset sharply higher sales, but results beat Wall Street expectations.

The U.S. drugmaker said it lost $3.4 billion in the fourth quarter, or $2.08 per share, compared with a year-earlier profit of $182 million, or 12 cents per share.

Excluding special items, Schering-Plough [SGP  Loading...      ()   ] earned 27 cents per share. Analysts on average expected 24 cents per share, according to Reuters Estimates.

"It looks like a solid quarter, and the quality of earnings was reasonably good," Leerink Swann analyst Seamus Fernandez said. Schering-Plough's better-than-expected performance was largely due to favorable foreign exchange factors and impressive sales of cholesterol fighters Zetia and Vytorin, he said.

Quarterly sales jumped 41 percent to $3.7 billion, a bit higher than the $3.53 billion Reuters Estimates had forecast.

The growth, in part, resulted from $626 million in sales of Organon products during the period after the merger was completed in November.

Overall sales growth would have been 7 percentage points less if not for the weak dollar, which increases the value of sales overseas.

Global revenue from Zetia and Vytorin, which the company sells through a joint venture with Merck [MRK  Loading...      ()   ], jumped 34 percent to $1.46 billion.

The company does not record sales from the joint venture. But including its assumed half of the global cholesterol joint venture net sales, Schering-Plough's adjusted sales for the quarter would have risen 39 percent to $4.4 billion.

But sales of Zetia and Vytorin have begun to slip in the past month after Vytorin, in a closely followed study, proved no better than Merck's older cholesterol fighter Zocor to prevent buildup of fatty plaque in arteries.

Vytorin combines Zetia, which prevents the intestines from absorbing cholesterol, with Zocor, a generically available drug that limits the body's production of cholesterol.

A torrent of news coverage has questioned whether a 21-month delay by Schering-Plough Corp and Merck to publish the trial data was an effort to hide negative findings.

Schering-Plough Chief Executive Fred Hassan on Tuesday said findings from the so-called Enhance trial had been "mischaracterized," and that a full understanding of the data will not be possible until they are formally presented at a major cardiology meeting next month.

"This was one of those media-driven situations," he told analysts in a conference call, saying his company and Merck acted with integrity and good faith with respect to the study.

Copyright 2011 Thomson Reuters. Click for restrictions.

CNBC HIGHLIGHTS

  • Alternative Investing: A CNBC Special Report
  • Marketing clichés aside, sometimes diamonds are for investing.
  • Nordstrom
  • The ‘Fast Money’ traders weigh in on fashion related stocks from apparel to footwear.
  • Las Vegas
  • This list of the 10 most active cities for speed traps was compiled by Trapster.com. See if your town is there.
  • This Valentine’s Day should prove a love fest for restaurants, as many couples will be dining out.
  • Airdale Terrier
  • Here’s a look at Westminster Kennel Club’s most successful breeds—and how much they cost.
  • Jennifer Aniston and Justin Theroux home
  • What kind of homes do celebrity couples share? Here’s our updated list. Take a look.


Current DateTime: 09:37:12 10 Feb 2012
LinksList Documentid: 29778428

Current DateTime: 02:33:41 10 Feb 2012
LinksList Documentid: 29779196

Current DateTime: 11:35:13 10 Feb 2012
LinksList Documentid: 29779197

Current DateTime: 02:56:30 10 Feb 2012
LinksList Documentid: 29779199
CNBCCNBC
About CNBC  |  Site Map  |  Video Reprints   |  Advertise  |  Help  |  Contact
Privacy Policy  |     |  Terms of Service  |  Independent Programming Report
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2012 CNBC LLC.  All Rights Reserved.
A Division of NBCUniversal
Thomson ReutersThomson Reuters